Related Experiment Videos
Current drug development portfolio for antimalarial therapies
Giancarlo A Biagini1, Paul M O'Neill, Patrick G Bray
1Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK. biagini@liverpool.ac.uk
Current Opinion in Pharmacology
|August 9, 2005
Summary
Drug resistance in malaria parasites necessitates new treatments. A collaborative portfolio, managed by Medicines for Malaria Venture (MMV), is advancing safe, effective, and affordable antimalarial medicines through clinical development.
Area of Science:
- * Tropical Medicine
- * Parasitology
- * Drug Discovery
Background:
- * Rising parasite drug resistance to existing antimalarials poses a significant global health threat.
- * The need for a sustainable pipeline of new antimalarial drugs is critical.
Purpose of the Study:
- * To outline the collaborative effort in developing a portfolio of new antimalarial drugs.
- * To highlight the progress of drug candidates within the development pipeline.
Main Methods:
- * Multi-stakeholder collaboration involving the scientific community, pharmaceutical industry, and public organizations.
- * Portfolio management approach driven by Medicines for Malaria Venture (MMV).
Main Results:
- * A comprehensive antimalarial drug development portfolio has been established.
- * Several drug development projects have advanced to the clinical trial stage.
Conclusions:
- * The collaborative model is effectively driving the development of new antimalarial medicines.
- * Continued investment and partnership are essential to combat malaria drug resistance.